SEQUENT SCIENTIFIC LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125 INR | +0.12% |
|
+4.78% | +9.75% |
| Sales 2022 | 14.13B 169M 232M | Sales 2023 | 14.21B 170M 233M | Capitalization | 18.04B 216M 296M |
|---|---|---|---|---|---|
| Net income 2022 | 413M 4.95M 6.77M | Net income 2023 | -1.21B -14.54M -19.87M | EV / Sales 2022 | 2.55 x |
| Net Debt 2022 | 3.06B 36.7M 50.17M | Net Debt 2023 | 4.02B 48.21M 65.92M | EV / Sales 2023 | 1.55 x |
| P/E ratio 2022 |
81.1
x | P/E ratio 2023 |
-14.9
x | Employees | 1,301 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 45.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sequent Scientific Limited
More recommendations
| 1 day | +0.12% | ||
| 1 week | +4.78% | ||
| Current month | +8.37% | ||
| 1 month | +10.04% | ||
| 3 months | -7.44% | ||
| 6 months | +25.58% | ||
| Current year | +9.75% |
1 week
119.55
127.90
1 month
114.90134.95
Current year
112.00155.45
1 year
70.15155.45
3 years
61.80336.40
5 years
52.00336.40
10 years
42.45336.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 22-04-10 | |
Saurav Bhala
DFI | Director of Finance/CFO | - | 11-05 |
Prasad Lad
ADM | Chief Administrative Officer | - | 13-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | 20-08-16 |
| Chairman | 76 | 20-08-24 | |
| Director/Board Member | 64 | 20-08-24 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 125 | +0.12% | 64,472 |
| 24-04-25 | 124.8 | -0.99% | 76,875 |
| 24-04-24 | 126 | +2.98% | 116,710 |
| 24-04-23 | 122.4 | -0.85% | 104,055 |
| 24-04-22 | 123.4 | +3.52% | 50,798 |
Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am
More quotes
SeQuent Scientific Limited is an India-based animal health company. The Company provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The Company operates through the pharmaceuticals segment. The Company is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. It is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. It provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.75% | 372M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SEQUENT Stock
